The spine company intends to use the proceeds to sustain global commercialization of its three minimally invasive products to treat degenerative disc disease with spinal fusion and vertebral compression fractures. It will also be used for additional initiatives to bring its fusion and VCF products to the U.S. market.
The three products include Benvenue Medical’s Kiva VCF Treatment System, Blazer Vertebral Augmentation System and Luna Interbody Spacer System.
More Articles on Orthopedic Devices:
Orthopedic Extremity Device Market to Surge Past $4.2B by 2016
Robert Wynalek Named Chief Operating and Commercialization Officer of Discgenics
NLT SPINE Reports Positive Clinical Results With PROW FUSION
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
